← FDA DRUG APPROVALS

FDA BLA · BLA761298

PAVBLU

aflibercept-ayyh

Sponsor: AMGEN INC

APPLICATION
BLA761298
TYPE
BLA
ORIGINAL APPROVAL
2024-08-23
LATEST ACTION
2026-04-28
ROUTE
INTRAVITREAL, INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription

Products

PAVBLUPrescription
AFLIBERCEPT-AYYH 2 mg (0.05 mL of 40 mg/mL) · INJECTABLE · INJECTION

Approval history

2026-04-28Bioequivalence · Supplement 5LetterAP
2024-08-23UNKNOWN · Original · standardLabelAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Biologics industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →